window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : March 11, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Confo Therapeutics

  • Biotech,Drug Development,Pharmaceuticals and therapeutics

    Confo therapeutics nominates SSTR5 agonist antibody CFTX-2034 for post-bariatric hypoglycemia

    Confo Therapeutics has selected CFTX-2034, an SSTR5 agonist antibody, as [...]

    December 19, 2025
  • Biologics & Biosimilars,Biotech,Drug Development,Research & Development,Technology and platforms

    Confo Therapeutics secures VLAIO grant to develop ultra-long-acting GPCR antibody therapies

    Confo Therapeutics has been awarded a EUR 1 million grant [...]

    October 8, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  •
    ViiV Healthcare reports 12-month data showing lotivibart maintains viral suppression in ultra long-acting HIV regimen
    Categories: Clinical Development, Infectious Diseases, Patient Centricity, Precision medicine
  • SPT Labtech and Illumina to develop automated platform for decentralised oncology genomics
    Categories: Diagnostics, Oncology, Partnerships & Funding
  • Young adults in US, UK and Australia hit hardest by global mental health decline
    Categories: Clinical studies, Digital Health, Global health, Mental health, Neurosciences
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top